Given a question and a context passage, generate the answer having the word or phrase from the context passage. Here, the answer should be a shortest continous span from the passage.
--------
Question: Context: Mowat-Wilson syndrome (MWS) is characterized by severe mental retardation with seizures, specific facial dysmorphism, Hirschsprung disease, anomalies of the corpus callosum, and genitourinary and cardiac malformations. The cause of MWS is a de novo mutation in the ZEB2 gene. This report describes a Turkish boy who was clinically diagnosed with MWS and had his diagnosis confirmed by molecular analysis of the ZEB2 gene. The investigation identified a heterozygous complex rearrangement in exon 8 of ZEB2, specifically a 48-nucleotide deletion and a 44-nucleotide insertion that caused a frameshift. MWS is a relatively newly identified disorder, and even MWS patients without Hirschsprung disease can be diagnosed easily based on clinical findings alone. 
 Question: Which gene is responsible for the development of the Mowat-Wilson syndrome?

Answer: zeb2


Question: Context: One day Mr. White gave his wife ten pounds for her birthday -- ten new pound notes. So Mrs. White went out shopping. She waited for a bus, got on it and sat down next to an o1d 1ady. After a while, Mrs. White noticed that the old 1ady's handbag was open. Inside it, she saw a wad of pound notes exactly like the ones her husband had given her. So she quickly looked into her own bag -- the notes had gone! Mrs. White was sure that the o1d lady next to her had stolen them. She immediately thought of calling the police. But as she disliked making a fuss , she decided to take back the money from the old 1ady's hand bag and say nothing about it. She looked around to make sure nobody was watching. Then she carefully put her hand into the o1d lady's bag, took the notes, and put them into her own handbag. When she got home that evening, Mrs. White showed her husband the beautiful hat she had bought. "How did you pay for it?" Mr. White asked. "With the money you gave me for my birthday, of course" she answered. "Oh? What's that, then?" he asked, as he pointed to a wad of pound notes on the table. 
 Question: What did Mrs. White use the money given by her husband for?

Answer: nothing.


Question: Context: Imatinib was developed as the first molecularly targeted therapy to specifically inhibit the BCR-ABL kinase in Philadelphia chromosome (Ph)-positive chronic myeloid leukemia (CML). Because of the excellent hematologic and cytogenetic responses, imatinib has moved toward first-line treatment for newly diagnosed CML. However, the emergence of resistance to imatinib remains a major problem in the treatment of Ph-positive leukemia. Several mechanisms of imatinib resistance have been identified, including BCR-ABL gene amplification that leads to overexpression of the BCR-ABL protein, point mutations in the BCR-ABL kinase domain that interfere with imatinib binding, and point mutations outside of the kinase domain that allosterically inhibit imatinib binding to BCR-ABL. The need for alternative or additional treatment for imatinib-resistant BCR-ABL-positive leukemia has guided the way to the design of a second generation of targeted therapies, which has resulted mainly in the development of novel small-molecule inhibitors such as AMN107, dasatinib, NS-187, and ON012380. The major goal of these efforts is to create new compounds that are more potent than imatinib and/or more effective against imatinib-resistant BCR-ABL clones. In this review, we discuss the next generation of BCR-ABL kinase inhibitors for overcoming imatinib resistance. 
 Question: What tyrosine kinase, involved in a Philadelphia- chromosome positive chronic myelogenous leukemia, is the target of Imatinib (Gleevec)?

Answer:
bcr-abl